Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | MDS: what’s the impact of early diagnosis?

David Steensma • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes

David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses myelodysplastic syndromes (MDS) diagnostic patterns, early versus later diagnosis and the impact on patient outcomes. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from David Steensma

2:51
MDS and Agent Orange
David Steensma • 5 Mar 2020
0:43
MDS novel agents & HMAs
David Steensma • 5 Mar 2020
0:52
Azacitidine in the treatment of MDS
David Steensma • 5 Mar 2020
1:16
State of the art: MDS
David Steensma • 5 Mar 2020

Related Videos

5:27
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
2:12
AlloSCT for AML with MDS-related features as per the ICC and WHO 2022 classifications
Arnon Nagler • 16 Apr 2024
1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals